Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

In First-to-market Race For HAE, Lev Submits Cinryze Complete Response To FDA

15 Apr 2008

• By Jessica Merrill

Lev is only firm in the race with prophylactic data.

Related Content

Lev’s Cinryze To Get FDA Blood Products Advisory Committee Review

13 Mar 2008

CSL Behring Submits C1-INH For Hereditary Angioedema

06 Mar 2008

FDA “Approvable” For Lev’s Cinryze Opens Window For Jerini To Reach Market First

31 Jan 2008

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.